Sentence: This study analysed 126 patients with relapsed , advanced stage follicular lymphoma who received BEAM ( BCNU [ carmustine ] , cytarabine , etoposide , melphalan)-alemtuzumab allogeneic HSCT ( BEAM-allo ) ( n = 44 ) or BEAM-autologous HSCT ( BEAM-auto ) ( n = 82 ) .
Drug combination annotation:
[{'class': 'COMB', 'spans': ['carmustine', 'cytarabine', 'etoposide', 'melphalan)-alemtuzumab'], 'is_context_needed': True}]